Skye Bioscience, Inc.
SKYE
$0.72
$0.068.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -110.50% | -141.19% | -0.20% | 12.92% | 29.43% |
| Total Depreciation and Amortization | 142.18% | 373.45% | 428.62% | 277.84% | 140.31% |
| Total Amortization of Deferred Charges | -- | -100.00% | -86.36% | -36.20% | 81.57% |
| Total Other Non-Cash Items | 142.00% | 573.35% | -84.97% | -83.10% | -87.09% |
| Change in Net Operating Assets | 280.02% | 143.09% | 226.94% | -73.98% | -460.01% |
| Cash from Operations | -70.63% | -98.33% | -69.37% | -103.54% | -80.89% |
| Capital Expenditure | 99.61% | 96.39% | -3,293.75% | -11,462.59% | -12,630.95% |
| Sale of Property, Plant, and Equipment | -73.44% | -73.63% | -73.57% | -81.38% | -75.45% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -7,839.86% | -4,741.52% | -1,295.95% | -742.93% | -103.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -92.50% | -93.41% | -93.41% | 667.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.46% | -2,320.29% | -2,266.73% | -2,273.44% | -2,273.44% |
| Cash from Financing | -99.96% | -99.97% | -99.98% | -102.05% | 408.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -207.67% | -193.21% | -171.83% | -151.26% | 539.10% |